We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA

By LabMedica International staff writers
Posted on 22 Feb 2024

Globally, an alarming one in every five deaths is attributed to complications related to sepsis, with children accounting for 41% of these fatalities. More...

Common practice involves administering antibiotics to sepsis patients while waiting for blood culture results, which can contribute to antibiotic resistance. Ineffectively treating sepsis can be detrimental, as up to 30% of patients receive incorrect treatments, further elevating their risk of death. The critical nature of timely and accurate diagnosis in sepsis cases is underscored by the fact that the mortality risk escalates by 4% every hour the infection is not properly identified or treated. Now, a new analysis technique offers quicker and more precise pathogen detection in blood samples compared to traditional blood cultures, which are the standard in infection diagnosis.

The new method, called digital DNA melting analysis, has been developed by researchers at UC San Diego (La Jolla, CA, USA) and is capable of delivering results in less than six hours. This marks a significant improvement over the typical 15 hours to several days required by culture methods, depending on the pathogen involved. The process utilizes universal digital high-resolution DNA melting, involving heating DNA until it separates. Each DNA sequence reveals a unique signature during the melting process. By imaging and analyzing this process, machine learning algorithms can discern the types of DNA in the samples and identify pathogens. This method not only outpaces blood cultures in terms of speed but also has a substantially lower risk of generating false positives compared to other emerging DNA detection technologies, such as Next Generation Sequencing.

The research began with one milliliter of blood from each of 17 patients in a preliminary clinical study. These samples were collected concurrently with those for blood cultures from infants and toddlers. The researchers honed the DNA isolation process and machine learning techniques to minimize or eliminate interference from human DNA in contrast to pathogen DNA in the samples. They refined a machine learning algorithm to accurately distinguish between the melting curves of pathogens and background noise. This algorithm correlates the observed curves with a database of known DNA melt curves. Moreover, it can identify curves produced by organisms not in this database, which is particularly useful in detecting rare or emerging pathogens in a sample.

The results from this method were not only consistent with those obtained from blood cultures of the same samples, but they also did not yield any false positives. This contrasts with other tests based on nucleic acid amplification and next-generation DNA sequencing databases, which tend to amplify all present DNA, leading to false positives. Contamination from various sources such as the environment, test tubes, reagents, and skin can often lead to challenges in interpreting test results. This new method detected pathogens 7.5 hours to approximately 3 days faster than conventional blood cultures. Additionally, it provides more than just a binary positive or negative outcome; it quantifies the extent of pathogen presence in the samples. Future plans include conducting a more extensive clinical study and extending the methodology to adult patients.

“This is the first time this method has been tested on whole blood from patients suspected of having sepsis. So this study is a more realistic preview of how the technology could perform in real clinical scenarios,” said Stephanie Fraley, a professor at the UC San Diego. “We want to give doctors the ability to treat their patients based not on aggregate data, but with precise, accurate individual data, enabling truly personalized medicine.”

Related Links:
UC San Diego


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Serological Pipet Controller
PIPETBOY GENIUS
New
Biochemistry Analyzer
Chemi+ 8100
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.